SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

MARTINS, Sandro José; MODESTO DOS SANTOS, Vitorino; THOMMEN TELES, Ludmila  y  ALVES LEITE, Viviane. Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab. Rev. méd. Chile [online]. 2012, vol.140, n.6, pp. 763-766. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872012000600010.

    1. Bird BRJH, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24. [ Links ]

    2. Chang HR. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116: 2856-67. [ Links ]

    3. Yeh ETH, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004; 109: 3122-31. [ Links ]

    4. Untch M, Rezai M, Loibl S, Fasching PA, Houber J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the Gepar-Quattro Study. J Clin Oncol 2010; 28: 2024-31. [ Links ]

    5. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009; 100: 684-92. [ Links ]

    6. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37: 300-11. [ Links ]

    7. Safra T. Chemotherapeutics and cardiac toxicity: treatment considerations and management strategies. Commun Oncol 2007; 4: 540-8. [ Links ]

    8. Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-600. [ Links ]

    9. Gianni L, Dombernowsky P, Sledge G, Martinn M, Amadori D, Arbuck G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001; 12: 1067-73. [ Links ]

    10. Guarnieri V, Barbieri E, Dieci MV, Piacentini F, Conte P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat Rev 2010; 36: S62-6. [ Links ]

    11. Tanz R, Mahfoud T, Bazine A, Khmamouch R, Bensouda Y, Ismaili N, et al. Cardiac safety of trastuzumab in adjuvant: A review across 53 observations. J Gynecol Obstet Biol Reprod (Paris) 2011; 40: 144-8. [ Links ]

    12. Galderisi M, Marra F, Esposito R, Lomoriello VS, Pardo M, Divitiis O. Cancer therapy and cardiotoxicity: The need of serial doppler echocardiography. Cardiovasc Ultrasound 2007; 5 :4. doi: 10.1186/1476-7120-5-4. [ Links ]

    13. Saad A, Abraham J. Trastuzumab and cardiac toxicity: monitoring in the adjuvant setting. Commun Oncol 2007; 4: 739-44. [ Links ]

    14. Suter TM, Procter M, Van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007; 25: 3859-65. [ Links ]

    15. Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson, et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 2008; 15: 24-35. [ Links ]

    16. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57: 2263-70. [ Links ]